NeuroSense Therapeutics (NRSN) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.4 million vs $6.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRSN | SKYE |
|---|---|---|
| Share price | $3.58 | $1.68 |
| Market cap | $6.79M | $7.44M |
| 1-day change | -6.28% | +1.82% |
| EPS (TTM) | $-47.10 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.64 | $14.08 |
| 52-week low | $3.56 | $1.50 |
| Distance from 52-week high | -86.56% | -88.07% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +2618.72% | +3947.62% |
| Average volume | 21.29K | 89.28K |
| Shares outstanding | 1.90M | 4.43M |
| Employees | 17 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Healthcare · Biotechnology · 17 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
NRSN vs SKYE FAQ
Which is bigger, NeuroSense Therapeutics or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.44M compared with $6.79M for NeuroSense Therapeutics (NRSN).
Are NeuroSense Therapeutics and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.